TR200101549T2 - p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar. - Google Patents

p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar.

Info

Publication number
TR200101549T2
TR200101549T2 TR2001/01549T TR200101549T TR200101549T2 TR 200101549 T2 TR200101549 T2 TR 200101549T2 TR 2001/01549 T TR2001/01549 T TR 2001/01549T TR 200101549 T TR200101549 T TR 200101549T TR 200101549 T2 TR200101549 T2 TR 200101549T2
Authority
TR
Turkey
Prior art keywords
protein
stimulating
methods
family
structural stability
Prior art date
Application number
TR2001/01549T
Other languages
English (en)
Inventor
Anne Coffey Heather
Damian Connell Richard
Ann Foster Barbara
Rastinejad Farzan
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200101549T2 publication Critical patent/TR200101549T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulus, kanser tedavisinin sahasindadir. Özellikle mevcut bulus, kanser ile ilgili düzenleyici proteinlerin mutant ve mutant olmayan formlari ile etkilesebilen farmasötik bilesik saglar; böylece mutant protein, diger makromoleküllerle uygun sekilde etkilesme kapasitesini yeniden kazanir ve böylece dogal tipteki aktivitesinin tümü veya bir kismi canlandirilir veya dengelenir. Düzenleyici proteinler arasinda örnegin; p53, p63 ve p73 gibi p53 protein familyasindan üyeleri kapsar. Bulusa ait bilesikler, kanser tedavisinde faydalidir. Bu farmakolojik bilesiklerin taranmasina yönelik metotlar da saglanmistir.
TR2001/01549T 1998-12-02 1999-12-01 p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar. TR200101549T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11054298P 1998-12-02 1998-12-02

Publications (1)

Publication Number Publication Date
TR200101549T2 true TR200101549T2 (tr) 2001-11-21

Family

ID=22333594

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01549T TR200101549T2 (tr) 1998-12-02 1999-12-01 p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar.

Country Status (25)

Country Link
US (1) US20020048271A1 (tr)
EP (1) EP1137418A2 (tr)
JP (2) JP2002531396A (tr)
KR (1) KR20010086073A (tr)
CN (1) CN1329493A (tr)
AP (1) AP2001002153A0 (tr)
AU (1) AU1290700A (tr)
BG (1) BG105599A (tr)
BR (1) BR9915940A (tr)
CA (1) CA2350597A1 (tr)
EA (1) EA003326B1 (tr)
EE (1) EE200100302A (tr)
HK (1) HK1041644A1 (tr)
HR (1) HRP20010414A2 (tr)
HU (1) HUP0201215A2 (tr)
ID (1) ID29061A (tr)
IL (1) IL143094A0 (tr)
IS (1) IS5943A (tr)
NO (1) NO20012737L (tr)
OA (1) OA11722A (tr)
PL (1) PL348310A1 (tr)
TR (1) TR200101549T2 (tr)
WO (1) WO2000032175A2 (tr)
YU (1) YU35401A (tr)
ZA (1) ZA200104210B (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20030022243A1 (en) * 2001-06-20 2003-01-30 Les Kondejewski Protein aggregation assays and uses thereof
EP1414846A2 (en) * 2001-08-10 2004-05-06 Medical Research Council Molecule
AU2003298512A1 (en) * 2002-05-06 2004-05-04 Colorado State University Research Foundation Genotoxicity analysis
WO2004030671A2 (en) * 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
DE60307049T2 (de) * 2003-04-25 2007-02-08 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1687275A4 (en) * 2003-11-21 2009-01-14 Merck & Co Inc PYRIDINE-4-YLAMINE COMPOUNDS SUITABLE FOR THE TREATMENT OF NEUROPATHIC PAIN
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
WO2005061001A1 (ja) * 2003-12-24 2005-07-07 Locomogene, Inc. 癌の抑制方法
EP1781293A1 (en) * 2004-06-04 2007-05-09 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US20070021433A1 (en) * 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
MX2008000744A (es) * 2005-07-15 2008-03-10 Schering Corp Derivados de quinazolina utiles en el tratamiento del cancer.
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
CA2644649C (en) 2006-03-22 2014-06-17 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
MY162844A (en) 2006-07-10 2017-07-31 The Trustee Of Columbia Univ In The City Of New York Anti-cocaine compositions and treatment
WO2008155441A1 (en) * 2007-06-20 2008-12-24 Marikki Laiho Activators and therapeutic applications thereof
ES2510551T3 (es) 2007-07-10 2014-10-21 The Trustees Of Columbia University In The City Of New York Termoestabilización de proteínas
ES2534899T3 (es) 2007-08-06 2015-04-30 Janssen Pharmaceutica, N.V. Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
AU2010210178B2 (en) 2009-02-04 2014-06-05 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
US20130102627A1 (en) * 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN102660257B (zh) * 2012-05-22 2013-11-27 南京邮电大学 吩噻嗪基喹唑啉类荧光离子探针及其应用
LT3201234T (lt) * 2014-09-30 2019-03-12 Diadem S.R.L. Antikūnas, surišantis linijinį žmogaus p53 epitopą, ir jo panaudojimas diagnostikai
CN105399670B (zh) * 2015-12-02 2018-04-17 广西中医药大学 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途
CN105418501B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
CN105399671B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
JP7072508B2 (ja) * 2016-02-04 2022-05-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用
CA3010847A1 (en) 2016-02-19 2017-08-24 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CN109694358B (zh) * 2019-01-23 2022-02-08 广西师范大学 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用
BR112022005460A2 (pt) 2019-09-23 2022-08-16 Pmv Pharmaceuticals Inc Métodos e compostos para a restauração da função de p53 mutante
MX2022015793A (es) 2020-06-24 2023-02-27 Pmv Pharmaceuticals Inc Terapia de combinacion para tratamiento de cancer.
GB202111035D0 (en) * 2021-07-30 2021-09-15 Vestlandets Innovasjonsselskap As Therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
DK0746613T3 (da) * 1994-03-08 2006-09-25 Sloan Kettering Inst Cancer Rekombinante humaniserede antistoffer mod FB5
ATE354638T1 (de) * 1994-12-13 2007-03-15 Human Genome Sciences Inc Menschlicher gewebsinhibitor von metalloproteinase-4
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
WO1997037645A1 (en) * 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
DK0923561T3 (da) * 1996-08-28 2003-02-24 Procter & Gamble Heterocykliske metalloproteaseinhibitorer
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
FI105554B (fi) * 1998-05-13 2000-09-15 Galilaeus Oy Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU5197599A (en) * 1998-08-12 2000-03-06 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
WO2001028550A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
US6372785B1 (en) * 2000-05-04 2002-04-16 Keith Chan, President Globoasia, Llc Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6391916B1 (en) * 2000-07-21 2002-05-21 The Hong Kong University Of Science And Technology Enediyne derivatives

Also Published As

Publication number Publication date
CA2350597A1 (en) 2000-06-08
AU1290700A (en) 2000-06-19
HK1041644A1 (zh) 2002-07-19
NO20012737L (no) 2001-07-09
AP2001002153A0 (en) 2001-06-30
KR20010086073A (ko) 2001-09-07
ZA200104210B (en) 2003-02-24
US20020048271A1 (en) 2002-04-25
NO20012737D0 (no) 2001-06-01
HUP0201215A2 (en) 2002-08-28
CN1329493A (zh) 2002-01-02
JP2002531396A (ja) 2002-09-24
ID29061A (id) 2001-07-26
YU35401A (sh) 2005-07-19
BR9915940A (pt) 2001-09-11
PL348310A1 (en) 2002-05-20
OA11722A (en) 2005-01-25
EP1137418A2 (en) 2001-10-04
IL143094A0 (en) 2002-04-21
HRP20010414A2 (en) 2002-06-30
EA003326B1 (ru) 2003-04-24
WO2000032175A2 (en) 2000-06-08
EE200100302A (et) 2002-08-15
JP2006166920A (ja) 2006-06-29
BG105599A (en) 2002-02-28
WO2000032175A3 (en) 2000-08-03
IS5943A (is) 2001-05-15
EA200100502A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
TR200101549T2 (tr) p53-Familyasından bir proteinin yapısal kararlılığının canlandırılmasına yönelik metotlar.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
TR199903331T2 (tr) Farnesil protein transferas engelleyicileri.
DE60005953D1 (de) Stapelbare statische mischelemente
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
DK550188A (da) Antigestagen- og antioestrogenvirksomme forbindelser til behandling af hormonafhaengige tumorer
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
DE69024965D1 (de) Dehydrodidemnin b
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69804659T2 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
FR2662698B1 (tr)
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
DE990441T1 (de) Arzneimittel zur behandlung von diabetischer nephrosis
DE69834057D1 (de) Echinocandinderivate, deren herstellung und deren verwendung zur bekämpfung von pilzen
DE69004301D1 (de) Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung.
ATE318844T1 (de) Wachstumsinhibierende agenzien gegen vitamin b12 bindungsstellen von transcobalamin-ii